VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial Neoplasms

Mukherjee, Sudeshna; Pal, Mallika; Mukhopadhyay, Susmita; Das, Ira; Hazra, Rathin; Ghosh, Sue; Mondal, Rajib; Bal, Runa

doi:10.7860/jcdr/2017/24670.9737

Cited by 14 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 Mukherjee et al, determined the VEGF expression by immunohistochemistry. 10 Among the 22 malignant cases, 18 (81.8%) were high expressers, only 3 (13.6%) were low expressers and expression was absent in one case. 11 cases out of 14 of high grade serous papillary cystadenocarcinoma, all five cases of mucinous cystadenocarcinoma and the two cases of endometrioid carcinoma showed high VEGF expression.…”

Section: Histopathological Typementioning

confidence: 91%

“…VEGF is detectable by immunostaining in most ovarian tumors and omental metastases and is measurable in the ascites fluid and serum of patients with ovarian cancer. 3,10…”

Section: Vegf As An Angiogenic Factor In Ovarian Cancermentioning

confidence: 99%

“…Importantly, VEGF, VEGFR-1,and VEGFR-2 expressions are cancer-specific, with strong expression being noted in malignant tumors, intermediate expression in borderline tumors, and weak or no staining in normal ovarian tissue. 10 Other members of the VEGF signaling pathways are expressed in ovarian tumors, including neuropilin and VEGFR-3 that is implicated in lymphangiogenesis and ascites formation. 20 Aside from promoting angiogenesis, through direct stimulation of endothelial cells, VEGF exerts other important functions in OC.…”

Section: Vegf Biological Behavior In Ovarian Cancermentioning

confidence: 99%

“…High levels of VEGF in serum and ascites, and high VEGF expression on ovarian carcinoma tumors, have been associated with ovarian tumor progression and poor prognosis. 3,[7][8][9][10][11] its diffuse symptoms. The lethality of ovarian carcinoma primarily stems from the inability to detect the disease at an early, organ-confined stage, and the lack of effective therapies for advanced-stage metastasizing disease.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Vascular endothelial growth factor correlation with clinicopathological parameters in ovarian cancer

Egiz

Masoud

Ellakwa

et al. 2019

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is one of the most lethal gynaecologic malignancies with an increasing incidence worldwide; there is an increasing need for the identification of novel prognostic biomarkers in EOC patients. Given the key role of angiogenesis and growth factors in the biology of tumorigenesis, vascular endothelial growth factor (VEGF) is considered a milestone in the process of ovarian cancer progression and invasiveness. Authors aimed in the present study to evaluate the relevance of serum level of VEGF with clinicopathological parameters in patients with EOC. VEGF is reported to be correlated with variable parameters in EOC patients including International Federation of Gynecology and Obstetrics (FIGO) classification, lymph nodal involvement and ascites formation. In the following review, authors discussed these correlations and distinguished the possible future role of VEGF as a promising prognostic biomarker for EOC patients.

show abstract

Section: Histopathological Typementioning

confidence: 91%

“…VEGF is detectable by immunostaining in most ovarian tumors and omental metastases and is measurable in the ascites fluid and serum of patients with ovarian cancer. 3,10…”

Section: Vegf As An Angiogenic Factor In Ovarian Cancermentioning

confidence: 99%

Section: Vegf Biological Behavior In Ovarian Cancermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vascular endothelial growth factor correlation with clinicopathological parameters in ovarian cancer

Egiz

Masoud

Ellakwa

et al. 2019

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…A family of Ab-photoCORM conjugates was synthesized ( Table 1) using this synthetic strategy with commercially available mouse monoclonal IgG raised against four surfaceexpressed antigens implicated in ovarian cancer, namely homing cell adhesion molecule (HCAM), 17 epithelial cell adhesion molecule (EpCAM), 18 glucose transporter 3 (GLUT3), 19 and vascular endothelial growth factor A (VEGF). 20 Immunoblot analysis of whole cell lysates of cell line models utilized, OVCAR-5 and SKOV-3, conrmed the presence of the antigens recognized by the family of Ab-photoCORMs ( Fig. 5A).…”

Section: Construction Of Ab-photocorm Conjugatementioning

confidence: 99%

Diminished viability of human ovarian cancer cells by antigen-specific delivery of carbon monoxide with a family of photoactivatable antibody-photoCORM conjugates

et al. 2020

View full text Add to dashboard Cite

Carbon monoxide (CO)-releasing antibody conjugates were synthesized utilizing a photoactivatable COreleasing molecule (photoCORM) and mouse monoclonal antibodies linked by a biotin-streptavidin system. Different monoclonal antibodies raised against different surface-expressed antigens that are implicated in ovarian cancer afforded a family of antibody-photoCORM conjugates (Ab-photoCORMs). In an immunosorbent/cell viability assay, Ab-photoCORMs accumulated onto ovarian cancer cells expressing the target antigens, delivering cytotoxic doses of CO in vitro. The results described here provide the first example of an "immunoCORM", a proof-of-the-concept antibody-drug conjugate that delivers a gaseous molecule as a warhead to ovarian cancer. † Electronic supplementary information (ESI) available: Synthetic scheme and calculations for CO release (Schemes S1 and S2). Spectroscopic, chromatography and mass spectrometry data ( Fig. S1-S4, S8 and S9). Myoglobin assays and cell toxicity/viability data (Fig. S5-S7 and S10-S13). Description of the experimental procedures. See Scheme 1 Live-cell, immunosorbent assay scheme utilized for assessment of the efficacy of antigen-recognition of an antibody-(photoactivated carbon monoxide-releasing molecule) conjugate (Ab-photoCORM) to deliver cytotoxic levels of carbon monoxide to ovarian cancer cells compared to a non-specific Ab-photoCORM conjugate.This journal is

show abstract

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer (OC) is associated with poor survival because there are a limited number of effective therapies. Two processes key to OC progression, angiogenesis and immune evasion, act synergistically to promote tumor progression. Tumor-associated angiogenesis promotes immune evasion, and tumor-related immune responses in the peritoneal cavity and tumor microenvironment (TME) affect neovascular formation. Therefore, suppressing the angiogenic pathways could facilitate the arrival of immune effector cells and reduce the presence of myeloid cells involved in immune suppression. To date, clinical studies have shown significant benefits with antiangiogenic therapy as first-line therapy in OC, as well as in recurrent disease, and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab is now an established therapy. Clinical data with immunomodulators in OC are more limited, but suggest that they could benefit some patients with recurrent disease. The preliminary results of two phase III trials have shown that the addition of immunomodulators to chemotherapy does not improve progression-free survival. For this reason, it could be interesting to look for synergistic effects between immunomodulators and other active drugs in OC. Since bevacizumab is approved for use in OC, and is tolerable when used in combination with immunotherapy in other indications, a number of clinical studies are underway to investigate the use of bevacizumab in combination with immunotherapeutic agents in OC. This strategy seeks to normalize the TME via the anti-VEGF actions of bevacizumab, while simultaneously stimulating the immune response via the immunotherapy. Results of these studies are awaited with interest.

show abstract

VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial Neoplasms

Cited by 14 publications

References 12 publications

Vascular endothelial growth factor correlation with clinicopathological parameters in ovarian cancer

Vascular endothelial growth factor correlation with clinicopathological parameters in ovarian cancer

Diminished viability of human ovarian cancer cells by antigen-specific delivery of carbon monoxide with a family of photoactivatable antibody-photoCORM conjugates

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

Contact Info

Product

Resources

About